PDE Inhibition and cognition enhancement

Expert Opinion on Therapeutic Patents

Volumn 22, Issue 4, 2012, Pages 349-354

  Blokland, Arjan ^a   Menniti, Frank S ^b   Prickaerts, Jos ^c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b Mnemosyne Pharmaceuticals Inc   (United States)

^c MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

brain; cAMP; cGMP; cognition; memory; phosphodiesterase

Indexed keywords

CYCLIC AMP; CYCLIC GMP; MESSENGER RNA; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR;

BRAIN REGION; COGNITION; COGNITIVE DEFECT; DRUG INHIBITION; DRUG MECHANISM; HUMAN; NERVE CELL PLASTICITY; NEUROTRANSMISSION; NONHUMAN; PATENT; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVIEW; RNA SPLICING; SCHIZOPHRENIA;

ANIMALS; BRAIN; COGNITION; COGNITION DISORDERS; CYCLIC AMP; CYCLIC GMP; DRUG DESIGN; HUMANS; MEMORY; PATENTS AS TOPIC; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES;

EID: 84859625177     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2012.674514     Document Type: Review

References (27)

1. Francis SH, Blount MA, Corbin JD. Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions. Physiol Rev 2011;91:651-90
2. Bender AT, Beavo JA. Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 2006;58:488-520 (Pubitemid 44394910)
3. Halene TB, Siegel SJ. PDE inhibitors in psychiatry - future options for dementia, depression and schizophrenia? Drug Discov Today 2007;12:870-8 (Pubitemid 47539966)
4. Rahimi R, Ghiasi S, Azimi H, et al. A review of the herbal phosphodiesterase inhibitors; future perspective of new drugs. Cytokine 2010;49:123-9
5. Schoffelmeer AN, Wardeh G, Mulder AH. Cyclic AMP facilitates the electrically evoked release of radiolabelled noradrenaline, dopamine and 5-hydroxytryptamine from rat brain slices. Naunyn Schmiedebergs Arch Pharmacol 1985;330:74-6 (Pubitemid 15068192)
6. Nishi A, Snyder GL. Advanced research on dopamine signaling to develop drugs for the treatment of mental disorders: biochemical and behavioral profiles of phosphodiesterase inhibition in dopaminergic neurotransmission. J Neurosci 2010;114:6-16
7. Blokland A, Boess F. Use of behavioral and LTP models in the development of memory-improving drugs. Expert Opin Drug Discov 2008;3:1067-80
8. Raymond CR. LTP forms 1, 2 and 3: different mechanisms for the "long" in long-term potentiation. Trends Neurosci 2007;30:167-75 (Pubitemid 46482683)
9. Deshmukh R, Sharma V, Mehan S, et al. Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine - a PDE1 inhibitor. Eur J Pharmacol 2009;620:49-56
10. Boess FG, Hendrix M, Van der Staay FJ, et al. Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 2004;47:1081-92 (Pubitemid 39535847)
11. Rutten K, Prickaerts J, Blokland A. Rolipram reverses scopolamine-induced and time-dependent memory deficits in object recognition by different mechanisms of action. Neurobiol Learn Mem 2006;85:132-8 (Pubitemid 43247839)
12. van der Staay FJ, Rutten K, Barfacker L, et al. The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents. Neuropharmacology 2008;55:908-18
13. Reneerkens OA, Rutten K, Steinbusch HW, et al. Selective phosphodiesterase inhibitors: a promising target for cognition enhancement. Psychopharmacology (Berl) 2009;202:419-43 Overview of the role of different PDE inhibitors in cognitive functions.
14. Prickaerts J, de Vente J, Honig W, et al. Increasing hippocampal cGMP, but not cAMP, levels improves memory performance in an object recognition task in rats. Eur J Pharmacol 2002;436:83-7
15. Marte A, Pepicelli O, Cavallero A, et al. In vivo effects of phosphodiesterase inhibition on basal cyclic guanosine monophosphate levels in the prefrontal cortex, hippocampus and cerebellum offreely moving rats. J Neurosci Res 2008;86:3338-47
16. Schmidt CJ. Phosphodiesterase inhibitors as potential cognition enhancing agents. Curr Top Med Chem 2010;10:222-30
17. Lakics V, Karran EH, Boess FG. Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues. Neuropharmacology 2010;59:367-74 Comprehensive analysis of the localization and expression of mRNA of the different PDE subfamilies in brain and peripheral tissue.
18. Menniti FS, Chappie TA, Humphrey JM, et al. Phosphodiesterase 10A inhibitors: a novel approach to the treatment of the symptoms of schizophrenia. Curr Opin Investig Drugs 2007;8:54-9 (Pubitemid 46438266)
19. Giralt A, Saavedra A, Carreton O, et al. Increased PKA signaling disrupts recognition memory and spatial memory: role in Huntington's disease. Hum Mol Genet 2011;20:4232-47
20. Bruno O, Fedele E, Prickaerts J, et al. GEBR-7b, a novel PDE4D selective inhibitor that improves memory in rodents at non-emetic doses. Br J Pharmacol 2011;164:2054-63
21. Reyes-Irisarri E, Markerink-Van Ittersum M, Mengod G, et al. Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer's disease human brains. Eur J Neurosci 2007;25:3332-8 (Pubitemid 46872773)
22. Domek-Lopacinska K, Strosznajder JB. The effect of selective inhibition of cyclic GMP hydrolyzing phosphodiesterases 2 and 5 on learning and memory processes and nitric oxide synthase activity in brain during aging. Brain Res 2008;1216:68-77
23. Krokera KS, Rastb G, Giovanninic R, et al. Inhibition of acetylcholinesterase and phosphodiesterase-9A has differential effects on hippocampal early and late LTP. Neuropharmacology 2012;62:1964-74
24. Xu Y, Zhang HT, O'Donnell JM. Phosphodiesterases in the central nervous system: implications in mood and cognitive disorders. Handb Exp Pharmacol 2011;204:447-85 A thorough overview of the possible applications of PDE inhibitors in depressive and cognitive disorders.
25. Rodefer JS, Saland SK, Eckrich SJ. Selective phosphodiesterase inhibitors improve performance on the ED/ID cognitive task in rats. Neuropharmacology 2012;62:1182-1190
26. Burgin AB, Magnusson OT, Singh J, et al. Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety. Nat Biotechnol 2010;28:63-70 A first paper suggesting an allosteric modulation of PDE subfamily (4D) with a preferred mechanism of action as compared to available PDE4 inhibitors.
27. Available from: http://clinicaltrials.gov/